Business UpdateAug 5, 2026, 09:33 AM
Citius Oncology LYMPHIR New Accounts Up 78% Q/Q; $400M Market
AI Summary
Citius Oncology, Inc. announced strong commercial momentum for its cancer treatment, LYMPHIR. New institutional accounts ordering LYMPHIR increased by 78% quarter over quarter, and total institutional vial orders rose 31% during the quarter ended June 30, 2026. The company also reported near-universal payer coverage and an estimated initial market for LYMPHIR in cutaneous T-cell lymphoma (CTCL) exceeding $400 million.
Key Highlights
- New institutional accounts ordering LYMPHIR increased 78% quarter over quarter.
- Total institutional vial orders for LYMPHIR rose 31% during the quarter.
- LYMPHIR is now available in 42 institutions, including academic and NCCN centers.
- The initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR exceeds $400 million.
- LYMPHIR has secured near-universal payer coverage, expanding market access.
- Citius Oncology targets formulary inclusion with 100 priority institutions by year-end.
Price Impact
More from CTOR
Clinical TrialJun 1, 4:30 PM
Citius Oncology: LYMPHIR Combo Shows Promising Phase 1 Data in Gynecologic Cancers
Quarterly ResultMay 15, 4:49 PM
Citius Oncology Q2 Net Revenue $1.7M; Secures $36.5M Financing
Quarterly ResultMay 15, 4:38 PM
Citius Oncology Reports Q2 Net Loss $32.1M; Raises $21.5M Amid Going Concern